Friday, October 16, 2026

Copper Futures Slides By 8% In The Last 21 Sessions

Copper Futures Slides By 8% In The Last 21 Sessions

(VIANEWS) - Copper (HG) has been up by 8.72% for the last 21 sessions. At 20:51 EST on Thursday, 25 May, Copper (HG) is $3.60.

Volume

Today's last reported volume for Copper is 1407, 99.99% below its average volume of 13251970484.61.

Volatility

Copper's last week, last month's, and last quarter's current intraday variation average was a negative 1.01%, a negative 0.01%, and a positive 1.00%, respectively.

Copper's highest amplitude of average volatility was 1.08% (last week), 1.14% (last month), and 1.00% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Copper's commodity is considered to be overbought (>=80).

Previous days news about Copper (HG)

  • Copper: sluggish demand from China points to lower prices – ING. According to FXStreet on Wednesday, 24 May, "We expect Copper prices to remain volatile as the market will continue to react to any policy change from China. "

News about

  • Crude oil forecast: finding its summer range - 24 May 2023. According to DailyForex on Wednesday, 24 May, "Ultimately, the WTI Crude Oil and Brent markets are navigating a volatile landscape as they attempt to establish summer ranges. "
  • According to FXStreet on Thursday, 25 May, "At the time of writing, WTI Oil is trading in the mid$72s and Brent Crude Oil in the mid$76s. "
  • According to FXStreet on Thursday, 25 May, "That said, the EIA Crude Oil Stocks Change came in at -12.456M versus 0.775M market forecasts and 5.04M previous readings."

More news about Copper (HG).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com